# Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

> **NCT00421122** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 315 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** budesonide/formoterol (Symbicort)
- **DRUG:** budesonide (Pulmicort)
- **DRUG:** terbutaline sulfate (Bricasol)

## Key facts

- **NCT ID:** NCT00421122
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2009-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421122, "Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00421122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*